U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H28N2O.ClH
Molecular Weight 312.878
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETIDOCAINE HYDROCHLORIDE

SMILES

Cl.CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=LMWQQUMMGGIGJQ-UHFFFAOYSA-N
InChI=1S/C17H28N2O.ClH/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5;/h9-11,15H,6-8,12H2,1-5H3,(H,18,20);1H

HIDE SMILES / InChI

Molecular Formula C17H28N2O
Molecular Weight 276.417
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162

Etidocaine, marketed under the trade name Duranest, is a local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of using during dentistry is increased bleeding during surgery. Etidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

CNS Activity

Curator's Comment: http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2163529&blobtype=pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DURANEST

Approved Use

INDICATIONS AND USAGE. Duranest (Etidocaine HCl) Injections are indicated for infiltration anesthesia, peripheral nerve blocks (e.g., brachial plexus, intercostal, retrobulbar, ulnar, inferior alveolar), and central neural block (i.e., lumbar or caudal epidural blocks).

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.5 μg/mL
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.8 μg × h/mL
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.7 h
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Etidocaine, bupivacaine, and lidocaine seizure thresholds in monkeys.
1975 Apr
Central-nervous-system toxicity of local anesthetic mixtures in monkeys.
1977 Mar
Comparative CNS toxicity of lidocaine, etidocaine, bupivacaine, and tetracaine in awake dogs following rapid intravenous administration.
1983 Apr
Local anesthetic-induced toxicity may be modified by low doses of flumazenil.
1992
Relative neural toxicity of local anesthetics.
1993 May
Pain of injection and duration of anesthesia for intradermal infiltration of lidocaine, bupivacaine, and etidocaine.
1994 Jul
Molecular determinants of state-dependent block of Na+ channels by local anesthetics.
1994 Sep 16
Toxic systemic reactions of bupivacaine and etidocaine.
1995 Jan
From cocaine to ropivacaine: the history of local anesthetic drugs.
2001 Aug
Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit.
2001 Jan 5
Spectrophotometric determination of etidocaine in pharmaceutical (dental) formulation.
2002 Jul 20
[Local anesthetics. Differences and similarities in the "-cains"].
2003 Apr
Toxicity of local anaesthetics.
2003 Mar
Differential effects of uncharged aminoamide local anesthetics on phospholipid bilayers, as monitored by 1H-NMR measurements.
2005 May 1
Lipid rescue resuscitation from local anaesthetic cardiac toxicity.
2006
[Retrobulbar anesthesia during keratolplasty].
2006 Feb
Direct vasocontractile activities of bupivacaine enantiomers on the isolated rat thoracic aorta.
2010
Advances in labor analgesia.
2010 Aug 9
Progress in analgesia for labor: focus on neuraxial blocks.
2010 Aug 9
Cardiogenic shock associated with loco-regional anesthesia rescued with left ventricular assist device implantation.
2010 Dec 8
Circadian effects on neural blockade of intrathecal hyperbaric bupivacaine.
2010 Sep
Patents

Patents

Sample Use Guides

The maximum dose to be employed as a single injection should be determined on the basis of the status of the patient and the type of regional anesthetic technique to be performed. Although single injections of 450 mg have been employed for regional anesthesia without adverse effects, at present it is strongly recommended that the maximal dose as a single injection should not exceed 400 mg (approximately 8.0 mg/kg or 3.6 mg/lb based on a 50 kg person) with epinephrine 1:200,000 and 300 mg (approximately 6 mg/kg or 2.7 mg/lb based on a 50 kg person) without epinephrine.
Route of Administration: Intramuscular
In Vitro Use Guide
Rat brain type IIA Na+ channels expressed in Xenopus oocytes were stimulated infrequently (1 pulse per 20 s, all currents were elicited by 15-ms pulses to 0 mV.) This tonic block mainly reflects drug binding to resting channels, the channel state that predominated at the holding potential of -90 mV. Etidocaine (200 mkM) decrease activities of WT Type IIA Na+ channels on ~40%.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:59 GMT 2023
Edited
by admin
on Fri Dec 15 16:13:59 GMT 2023
Record UNII
G6N3B3U8E6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETIDOCAINE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
BUTANAMIDE, N-(2,6-DIMETHYLPHENYL)-2-(ETHYLPROPYLAMINO)-, MONOHYDROCHLORIDE
Common Name English
ETIDOCAINE HYDROCHLORIDE [MI]
Common Name English
DURANEST
Brand Name English
W-19053
Code English
DURANEST HYDROCHLORIDE
Common Name English
ETIDOCAINE HYDROCHLORIDE [VANDF]
Common Name English
ETIDOCAINE HYDROCHLORIDE [MART.]
Common Name English
Etidocaine hydrochloride [WHO-DD]
Common Name English
BUTANAMIDE, N-(2,6-DIMETHYLPHENYL)-2-(ETHYLPROPYLAMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
BUTANAMIDE, N-(2,6-DIMETHYLPHENYL)-2-(ETHYLPROPYLAMINO)-, (±)-, MONOHYDROCHLORIDE
Common Name English
ETIDOCAINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
ETIDOCAINE HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C245
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL492
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
WIKIPEDIA
Etidocaine hydrochloride
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
MERCK INDEX
m5181
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID70957895
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
EVMPD
SUB02037MIG
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
RXCUI
227221
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C77325
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
FDA UNII
G6N3B3U8E6
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
SMS_ID
100000087301
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
CAS
52300-99-9
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
SUPERSEDED
PUBCHEM
37498
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
DRUG BANK
DBSALT001431
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
ECHA (EC/EINECS)
253-144-3
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
CAS
36637-19-1
Created by admin on Fri Dec 15 16:13:59 GMT 2023 , Edited by admin on Fri Dec 15 16:13:59 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY